Physician profile
Brock E Harper
NPI 1700968005
$76,391.83
in general payments reported to CMS, 2019-2025
53 companies · $42K in 2025
The $42K reported for 2025 was more than what 96% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $8,208 · 2021: $3,758 · 2022: $3,301 · 2023: $4,399 · 2024: $4,824 · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $11K · Consulting Fee: $4,980 · Travel and Lodging: $4,330 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,066.00 |
| Food and Beverage | $10,586.51 |
| Consulting Fee | $4,980.00 |
| Travel and Lodging | $4,330.00 |
| Education | $118.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $44,231.61 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $5,004.06 | 2019-2025 | |
| Lilly USA, LLC | $4,954.05 | 2019-2024 | Taltz |
| Abbvie INC. | $4,134.01 | 2019-2025 | |
| Amgen INC. | $2,855.19 | 2019-2025 | Tavneos, Enbrel, Evenity |
| Ucb, INC. | $2,565.33 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $1,485.66 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $1,249.19 | 2024 | Tremfya |
| Genzyme Corporation | $1,127.09 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,022.05 | 2019-2025 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals LP | $878.27 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $811.00 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $751.32 | 2019-2025 | Orencia |
| Sanofi-Aventis U.S. LLC | $667.97 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $603.65 | 2020-2025 | Acthar |
Show all 52 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brock Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.